Cary Street Partners Financial LLC purchased a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 6,718 shares of the company's stock, valued at approximately $440,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. Bank of America Corp DE increased its stake in shares of AstraZeneca by 189.3% in the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after acquiring an additional 15,722,197 shares during the period. Marshall Wace LLP acquired a new stake in shares of AstraZeneca in the fourth quarter worth $254,018,000. Boston Partners grew its position in AstraZeneca by 9,985.6% during the fourth quarter. Boston Partners now owns 3,707,479 shares of the company's stock valued at $243,444,000 after buying an additional 3,670,719 shares during the period. Raymond James Financial Inc. acquired a new stake in AstraZeneca during the fourth quarter valued at $158,018,000. Finally, Alyeska Investment Group L.P. grew its position in AstraZeneca by 220.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 3,027,511 shares of the company's stock valued at $198,363,000 after buying an additional 2,083,645 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.
AstraZeneca Price Performance
Shares of NASDAQ AZN traded down $1.23 during trading on Tuesday, hitting $67.72. The company had a trading volume of 4,827,720 shares, compared to its average volume of 5,158,386. The stock has a fifty day simple moving average of $71.15 and a two-hundred day simple moving average of $69.61. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The firm has a market capitalization of $210.02 billion, a price-to-earnings ratio of 29.96, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm posted $2.06 earnings per share. On average, research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.
Wall Street Analysts Forecast Growth
AZN has been the topic of several analyst reports. Morgan Stanley initiated coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. Finally, UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $88.00.
Read Our Latest Stock Report on AZN
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
